Sumitomo Pharma (TSE:4506) Full Year 2025 Results
Key Financial Results
- Revenue: JP¥398.8b (up 27% from FY 2024).
- Net income: JP¥23.6b (up from JP¥315.0b loss in FY 2024).
- Profit margin: 5.9% (up from net loss in FY 2024).
- EPS: JP¥59.49 (up from JP¥793 loss in FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sumitomo Pharma Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 7.1%. Earnings per share (EPS) also surpassed analyst estimates by 72%.
The primary driver behind last 12 months revenue was the Pharmaceuticals - North America segment contributing a total revenue of JP¥251.8b (63% of total revenue). The largest operating expense was General & Administrative costs, amounting to JP¥180.6b (78% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of JP¥10.6b. Explore how 4506's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Japan.
Performance of the Japanese Pharmaceuticals industry.
The company's shares are down 3.6% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Sumitomo Pharma (including 3 which don't sit too well with us).
If you're looking to trade Sumitomo Pharma, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4506
Sumitomo Pharma
Engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally.
Slight and fair value.
Similar Companies
Market Insights
Community Narratives
